Literature DB >> 17305472

Physiological roles of G protein-coupled receptor kinases and arrestins.

Richard T Premont1, Raul R Gainetdinov.   

Abstract

Heterotrimeric G protein-coupled receptors (GPCRs) are found on the surface of all cells of multicellular organisms and are major mediators of intercellular communication. More than 800 distinct GPCRs are present in the human genome, and individual receptor subtypes respond to hormones, neurotransmitters, chemokines, odorants, or tastants. GPCRs represent the most widely targeted pharmacological protein class. Because drugs that target GPCRs often engage receptor regulatory mechanisms that limit drug effectiveness, particularly in chronic treatment, there is great interest in understanding how GPCRs are regulated, as a basis for designing therapeutic drugs that evade this regulation. The major GPCR regulatory pathway involves phosphorylation of activated receptors by G protein-coupled receptor kinases (GRKs), followed by binding of arrestin proteins, which prevent receptors from activating downstream heterotrimeric G protein pathways while allowing activation of arrestin-dependent signaling pathways. Although the general mechanisms of GRK-arrestin regulation have been well explored in model cell systems and with purified proteins, much less is known about the role of GRK-arrestin regulation of receptors in physiological and pathophysiological settings. This review focuses on the physiological functions and potential pathophysiological roles of GRKs and arrestins in human disorders as well as on recent studies using knockout and transgenic mice to explore the role of GRK-arrestin regulation of GPCRs in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305472     DOI: 10.1146/annurev.physiol.69.022405.154731

Source DB:  PubMed          Journal:  Annu Rev Physiol        ISSN: 0066-4278            Impact factor:   19.318


  216 in total

1.  Connexin43 interacts with βarrestin: a pre-requisite for osteoblast survival induced by parathyroid hormone.

Authors:  Nicoletta Bivi; Virginia Lezcano; Milena Romanello; Teresita Bellido; Lilian I Plotkin
Journal:  J Cell Biochem       Date:  2011-10       Impact factor: 4.429

2.  Overlapping and distinct roles of GRK5 in TLR2-, and TLR3-induced inflammatory response in vivo.

Authors:  Nandakumar Packiriswamy; Sitaram Parvataneni; Narayanan Parameswaran
Journal:  Cell Immunol       Date:  2011-10-28       Impact factor: 4.868

3.  AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release.

Authors:  Jacob Bendor; José E Lizardi-Ortiz; Robert I Westphalen; Markus Brandstetter; Hugh C Hemmings; David Sulzer; Marc Flajolet; Paul Greengard
Journal:  EMBO J       Date:  2010-07-27       Impact factor: 11.598

Review 4.  Control of autocrine and paracrine myocardial signals: an emerging therapeutic strategy in heart failure.

Authors:  Vincenzo Lionetti; Giacomo Bianchi; Fabio A Recchia; Carlo Ventura
Journal:  Heart Fail Rev       Date:  2010-11       Impact factor: 4.214

5.  Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets.

Authors:  Dongjun Li; Lauren D'Angelo; Massiel Chavez; Donna S Woulfe
Journal:  J Biol Chem       Date:  2010-11-24       Impact factor: 5.157

6.  M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1.

Authors:  Kok Choi Kong; Adrian J Butcher; Phillip McWilliams; David Jones; Jürgen Wess; Fadi F Hamdan; Tim Werry; Elizabeth M Rosethorne; Steven J Charlton; Sarah E Munson; Hannah A Cragg; Alison D Smart; Andrew B Tobin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

Review 7.  Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: a high-throughput screening approach.

Authors:  Wei Chen; Minyong Chen; Larry S Barak
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-05-27       Impact factor: 4.052

Review 8.  The emerging roles of β-arrestins in fibrotic diseases.

Authors:  Yuan-jing Gu; Wu-yi Sun; Sen Zhang; Jing-jing Wu; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-09-21       Impact factor: 6.150

9.  Selective deletion of GRK2 alters psychostimulant-induced behaviors and dopamine neurotransmission.

Authors:  Tanya L Daigle; Mark J Ferris; Raul R Gainetdinov; Tatyana D Sotnikova; Nikhil M Urs; Sara R Jones; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2014-04-29       Impact factor: 7.853

Review 10.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.